The treatment regimens for chronic wounds (diabetic foot ulcers and venous leg ulcers) in these studies involved repeated weekly dosing with topically applied αCT1 over a 3 month study period, with the independent contract research organization carrying out the work finding no occurrences of severe adverse events, including no evidence of immune responses to the peptide drug. This evidence concerns the gene TRAF3IP2 and diabetic foot.